Item 2.02. Results of Operations and Financial Condition.
On May 5, 2022, BeiGene, Ltd. (the "Company") announced its financial results
for the three months ended March 31, 2022. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 8.01. Other Events.
In its press release dated May 5, 2022, the Company also provided an update on
the first quarter of 2022 and recent business highlights and expected milestones
for the remainder of 2022 and 2023. The information in the press release set
forth under the headings "Recent Business Highlights", "Expected Milestones" and
"Forward-Looking Statements" is incorporated by reference into this Item 8.01 of
this Current Report on Form 8-K.
On May 4, 2022, the Company issued a press release announcing that the China
National Medical Products Administration granted conditional approval of
BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients
with relapsed or refractory (R/R) CD19-positive B-cell precursor acute
lymphoblastic leukemia. A copy of this press release is attached hereto as
Exhibit 99.2, and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release titled "BeiGene Reports First Quarter 2022 Financial Results"
issued by BeiGene, Ltd. on May 5, 2022
99.2 Press release titled "BeiGene Announces the Approval in China of BLINCYTO
(Blinatumomab) for Injection for Pediatric Patients with Relapsed or
Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)" issued by
BeiGene, Ltd. on May 4, 2022
104 The cover page from this Current Report on Form 8-K, formatted in Inline
XBRL
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses